This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LOS ANGELES, July 17, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy, today announced that it has extended its agreement with Taiho Pharmaceutical Co., Ltd. to provide testing and analyses services for specified molecular markers used in research, diagnosis and the therapeutic treatment of cancer.
Under the terms of the agreement, Response Genetics will receive a minimum of $950,000 for services provided during the extended term of January 1 through December 31, 2013.
"Response Genetics has and continues to provide Taiho with a comprehensive portfolio of gene expression assays and we are pleased to extend this relationship," said Thomas Bologna, Chairman and CEO of Response Genetics. "Response Genetics and Taiho share a commitment to provide services that foster the development of patient-centered medical treatment and we believe that the testing services resulting from this collaboration will yield actionable results important to patient care."
About Response Genetics, Inc.
Response Genetics, Inc. (the "Company") is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company's technologies enable extraction and analysis of genetic information derived from tumor cells stored as formalin-fixed and paraffin-embedded specimens. The Company's principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sale of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company's headquarters is located in Los Angeles, California. For more information, please visit
About Taiho Pharmaceutical Co., Ltd.
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. In the field of oncology in particular, Taiho Pharmaceutical is known as a leading company in Japan and around the world for developing innovative medicines for the treatment of cancer. In areas other than oncology, as well, the company creates quality products that effectively treat medical conditions and can help improve people's quality of life. The company was established in 1963 and its headquarters is located in Tokyo, Japan.